Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

ClinicalTrials.gov ID: NCT01482221

Public ClinicalTrials.gov record NCT01482221. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients With Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants

Study identification

NCT ID
NCT01482221
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
542 participants

Conditions and interventions

Interventions

  • AZD6765 iv Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 15, 2011
Primary completion
Aug 25, 2013
Completion
Aug 25, 2013
Last update posted
Apr 10, 2017

2011 – 2013

United States locations

U.S. sites
33
U.S. states
17
U.S. cities
33
Facility City State ZIP Site status
Research Site Chino California
Research Site Lond Beach California
Research Site San Diego California
Research Site Stanford California
Research Site New Heaven Connecticut
Research Site Fort Lauderdale Florida
Research Site Gainsville Florida
Research Site Lake City Florida
Research Site Miami Florida
Research Site Orlando Florida
Research Site St. Petersburg Florida
Research Site Atlanta Georgia
Research Site Decatur Georgia
Research Site Hoffman Estates Illinois
Research Site Joliet Illinois
Research Site Skokie Illinois
Research Site Lake Charles Louisiana
Research Site Shreveport Louisiana
Research Site Baltimore Maryland
Research Site Boston Massachusetts
Research Site Minneapolis Minnesota
Research Site St Louis Missouri
Research Site Willingboro New Jersey
Research Site Mount Kisco New York
Research Site New York New York
Research Site Rochester New York
Research Site Winston-Salem North Carolina
Research Site Cincinnati Ohio
Research Site Dayton Ohio
Research Site Philadelphia Pennsylvania
Research Site Dallas Texas
Research Site Houston Texas
Research Site Bellevue Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01482221, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 10, 2017 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01482221 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →